MRSN - メルサナ・セラピュ―ティクス （Mersana Therapeutics Inc.） メルサナ・セラピュ―ティクスMRSNのチャート
MRSNの企業情報
| symbol | MRSN |
|---|---|
| 会社名 | Mersana Therapeutics Inc （メルサナ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 メルサナ・セラピューティクス(Mersana Therapeutics Inc.)はバイオテクノロジー企業である。同社は抗体医薬複合体（ADC）パイプラインの発見と開発に従事する。同社はFleximerイムノコンジュゲート技術を活用した標的腫瘍治療薬パイプラインの推進に重点を置く。Fleximerプラットフォームにより、同社は特定特性を持つADCを設計し、癌の攻撃機会を管理できる。製品候補には、XMT-1522とXMT-1536が含まれる。ADC療法は抗癌剤との薬物コンジュゲートを操作して癌患者を治療する。DolaflexinはFleximerポリマーをリンカー化学物質とペアにしてADC療法を作成するFleximer抗体薬物接合プラットフォームである。 メルサナ・セラピュ―ティクスはアメリカのバイオ医薬品企業。臨床段階で、抗体医薬複合体(ADC)に焦点を当て、がん患者向けの治療法を開発する。免疫複合療法を開発し、比較的少量のHER2タンパク質を発現するXMT-1522を提供する。同社の「Dolaflexin」プラットフォ―ムを活用したパ―トナ―シップも展開する。本社はマサチュ―セッツ州ケンブリッジ。 Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines. |
| 本社所在地 | 840 Memorial Drive Cambridge MA 02139 USA |
| 代表者氏名 | David M. Mott デビッド・モット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-498-0020 |
| 設立年月日 | 37288 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 78人 |
| url | www.mersana.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mrsn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -46.81100 |
| 終値（lastsale） | 8.99 |
| 時価総額（marketcap） | 208149227.82 |
| 時価総額 | 時価総額（百万ドル） 185.69040 |
| 売上高 | 売上高（百万ドル） 16.78300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 89.18140 |
| 当期純利益 | 当期純利益（百万ドル） -46.45600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Mersana Therapeutics Inc revenues decreased 10% to $7.3M. Net loss increased 46% to $24.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $10.6M to $24.9M (expense) General and administrative increase from $2.2M to $7.8M (expense). |
MRSNのテクニカル分析
MRSNのニュース
After Sinking 1.05% During Past Week, Is Mersana Therapeutics Inc. (NASDAQ: MRSN) Still A Buy? 2022/09/08 16:40:00 Marketing Sentinel
Mersana Therapeutics Inc. (NASDAQ:MRSN)’s traded shares stood at 0.63 million during the latest session, with the company’s beta value hitting 1.73. At the last check today, the stock’s price was $7.92, to imply an increase of 2.46% or $0.19 in intraday trading. The MRSN share’s 52-week high remains $14.80, putting it -86.87% down since that … After Sinking 1.05% During Past Week, Is Mersana Therapeutics Inc. (NASDAQ: MRSN) Still A Buy? Read More »
Mersana Therapeutics Inc. (NASDAQ:MRSN) Is -0.63% Lower Than A Week Ago, Can It Hit Well Above -$0.05? 2022/09/02 12:00:00 Marketing Sentinel
In last trading session, Mersana Therapeutics Inc. (NASDAQ:MRSN) saw 1.38 million shares changing hands with its beta currently measuring 1.95. Company’s recent per share price level of $7.85 trading at $0.35 or 4.67% at ring of the bell on the day assigns it a market valuation of $792.85M. That closing price of MRSN’s stock is … Mersana Therapeutics Inc. (NASDAQ:MRSN) Is -0.63% Lower Than A Week Ago, Can It Hit Well Above -$0.05? Read More »
Mersana Therapeutics Inc. (NASDAQ: MRSN) Is Up 22.03% So Far This Year: What Will Happen Next? 2022/08/23 13:00:00 Stocks Register
The trading price of Mersana Therapeutics Inc. (NASDAQ:MRSN) closed higher on Monday, August 22, closing at $7.59, 1.47% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $7.35 and $7.81. In examining the 52-week price action we see that the stock hit a 52-week … Mersana Therapeutics Inc. (NASDAQ: MRSN) Is Up 22.03% So Far This Year: What Will Happen Next? Read More »
Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed (NASDAQ:MRSN) 2022/08/15 13:27:43 Seeking Alpha
Shares of Mersana are up 21% in 2022 and +168% over past 3 years, but it might be too speculative now. Click here for a full investment analysis of MRSN stock.
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful 2022/08/09 13:08:37 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc (NASDAQ: MRSN ) announced a global collaboration that provides GSK plc (NYSE: GSK ) an exclusive option to co-develop and commercialize XMT-2056. Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the U.S. Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners Clearside Biomedical Inc (NASDAQ: CLSD ) has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million . At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.
Why Mersana Therapeutics Inc. (NASDAQ: MRSN) Stock Should Not Be Discarded By Investors In 2022 2022/06/22 13:30:00 Marketing Sentinel
In the last trading session, 3.44 million shares of the Mersana Therapeutics Inc. (NASDAQ:MRSN) were traded, and its beta was 2.25. Most recently the company’s share price was $4.15, and it changed around $0.45 or 12.16% from the last close, which brings the market valuation of the company to $342.67M. MRSN currently trades at a … Why Mersana Therapeutics Inc. (NASDAQ: MRSN) Stock Should Not Be Discarded By Investors In 2022 Read More »
Insider Trading At Mersana Therapeutics Inc. (NASDAQ: MRSN): What Did We Note? 2022/06/08 13:30:00 Stocks Register
Mersana Therapeutics Inc. (NASDAQ:MRSN) traded at $3.40 at close of the session on Tuesday, 06/07/22, made an upward move of 2.41% on its previous day’s price. Looking at the stock we see that its previous close was $3.32 and the beta (5Y monthly) reads 2.42 with the day’s price range being $3.27 – $3.44. In … Insider Trading At Mersana Therapeutics Inc. (NASDAQ: MRSN): What Did We Note? Read More »
Mersana Therapeutics: High on Strong Insider Buying 2022/05/19 16:15:07 TipRanks
Mersana Therapeutics (NASDAQ: MRSN) is a biopharmaceutical company that discovers and develops “antibody-drug conjugate (ADC) therapies to treat patients fighting cancer.” It is a penny stock, with the stock closing at $3.29 on May 18. Shares of the company have dropped 12% in the past month, as in Q1, its net losses widened to $47.3 million, or $0.59 per share versus $34.7 million, or $0.50 per share in the same quarter a year back. Moreover, Mersana’s expenses are also rising as research and development expenses increased 30.6% year-over-year to $35.8 million in Q1. General and administrative expenses shot up to $12.8 million in Q1 versus $7.
Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug 2022/05/19 12:09:24 Benzinga
Mersana Therapeutics, Inc. (NASDAQ: MRSN ) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The company is planning to start a clinical study evaluating XMT-2056 for gastric and other cancers. Anna Protopapas, President and Chief Executive Officer, commented : “The FDA''s decision to grant orphan drug designation to XMT-2056 for the … Full story available on Benzinga.com
Mersana Therapeutics Inc. (NASDAQ: MRSN) Is A Buzzing Hot Stock 2022/05/18 13:30:00 Stocks Register
Mersana Therapeutics Inc. (NASDAQ:MRSN) traded at $3.37 at close of the session on Tuesday, 05/17/22, made an upward move of 8.01% on its previous day’s price. Looking at the stock we see that its previous close was $3.12 and the beta (5Y monthly) reads 2.42 with the day’s price range being $3.14 – $3.415. In … Mersana Therapeutics Inc. (NASDAQ: MRSN) Is A Buzzing Hot Stock Read More »
Mersana Therapeutics Inc Shares Near 52-Week Low - Market Mover 2021/07/24 18:27:22 Kwhen Finance
Mersana Therapeutics Inc (MRSN) shares closed today at 1.6% above its 52 week low of $11.71, giving the company a market cap of $827M. The stock is currently down 55.3% year-to-date, down 45.9% over the past 12 months, and down 15.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 2.0%. Trading Activity Trading volume this week was 55.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 1.6% lower than its 5-day moving average, 7.1% lower than its 20-day moving average, and 20.1% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 82.6% The company's stock price performance over the past 12 months lags the peer average by 124.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Mersana Therapeutics Inc Shares Fall 2.1% Below Previous 52-Week Low - Market Mover 2021/07/14 02:30:18 Kwhen Finance
Mersana Therapeutics Inc (MRSN) shares closed 2.1% lower than its previous 52 week low, giving the company a market cap of $896M. The stock is currently down 51.6% year-to-date, down 40.2% over the past 12 months, and down 7.9% over the past five years. This week, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.8%. Trading Activity Trading volume this week was 16.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance over the past 12 months lags the peer average by 110.8%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Mersana Therapeutics Inc Shares Close in on 52-Week Low - Market Mover 2021/07/10 00:34:35 Kwhen Finance
Mersana Therapeutics Inc (MRSN) shares closed today at 100.0% below its 52 week low of $12.59, giving the company a market cap of $895M. The stock is currently flat year-to-date, down 40.3% over the past 12 months, and down 8.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.4%. Trading Activity Trading volume this week was 67.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date is the same as the peer average. The company's stock price performance over the past 12 months lags the peer average by 120.2%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.